scPharmaceuticals Inc. (2SX.F)
| Previous close | 4.0200 |
| Open | 4.0200 |
| Bid | 4.1400 x 0 |
| Ask | 4.2600 x 0 |
| Day's range | 4.0200 - 4.0600 |
| 52-week range | 4.0000 - 11.2000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 150.904M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3200 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.67 |
GlobeNewswirescPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
Simply Wall St.Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...
Insider MonkeyscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript March 13, 2024 scPharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.35, expectations were $-0.48. SCPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to scPharmaceuticals Fourth Quarter and […]
